Premium
Healthcare-focussed private equity firm OrbiMed, which sealed one new deal last year after adding two new companies to its India portfolio in 2022, has set itself for a bumper profit as a company it virtually incubated and helped co-create from scratch is set to shower abnormal returns for the PE ......
This is a Premium article. Please subscribe or log in to read the full story!
Here's a selection of our recent premium content.
Already a member? Click here to log in.
